In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against Leishmania
One of the major drawbacks of current treatments for neglected tropical diseases is the low safety of the drugs used and the emergence of resistance. Leishmaniasis is a group of neglected diseases caused by protozoa of the trypanosomatidae family that lacks preventive vaccines and whose pharmacological treatments are scarce and unsafe. Combination therapy is a strategy that could solve the above-mentioned problems, due to the participation of several mechanisms of action and the reduction in the amount of drug necessary to obtain the therapeutic effect. In addition, this approach also increases the odds of finding an effective drug following the repurposing strategy. From the previous screening of two collections of repositioning drugs, we found that pyrvinium pamoate had a potent leishmanicidal effect. For this reason, we decided to combine it separately with two clinically used leishmanicidal drugs, miltefosine and paromomycin. These combinations were tested in axenic amastigotes of Leishmania infantum obtained from bone marrow cells and in intramacrophagic amastigotes obtained from primary cultures of splenic cells, both cell types coming from experimentally infected mice. Some of the combinations showed synergistic behavior, especially in the case of the combination of pyrvinium pamoate with paromomycin, and exhibited low cytotoxicity and good tolerability on intestinal murine organoids, which reveal the potential of these combinations for the treatment of leishmaniasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Tropical medicine and infectious disease - 9(2024), 2 vom: 25. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Melcón-Fernández, Estela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug combinations |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/tropicalmed9020030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368831027 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368831027 | ||
| 003 | DE-627 | ||
| 005 | 20240229164518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/tropicalmed9020030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM368831027 | ||
| 035 | |a (NLM)38393119 | ||
| 035 | |a (PII)30 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Melcón-Fernández, Estela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against Leishmania |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a One of the major drawbacks of current treatments for neglected tropical diseases is the low safety of the drugs used and the emergence of resistance. Leishmaniasis is a group of neglected diseases caused by protozoa of the trypanosomatidae family that lacks preventive vaccines and whose pharmacological treatments are scarce and unsafe. Combination therapy is a strategy that could solve the above-mentioned problems, due to the participation of several mechanisms of action and the reduction in the amount of drug necessary to obtain the therapeutic effect. In addition, this approach also increases the odds of finding an effective drug following the repurposing strategy. From the previous screening of two collections of repositioning drugs, we found that pyrvinium pamoate had a potent leishmanicidal effect. For this reason, we decided to combine it separately with two clinically used leishmanicidal drugs, miltefosine and paromomycin. These combinations were tested in axenic amastigotes of Leishmania infantum obtained from bone marrow cells and in intramacrophagic amastigotes obtained from primary cultures of splenic cells, both cell types coming from experimentally infected mice. Some of the combinations showed synergistic behavior, especially in the case of the combination of pyrvinium pamoate with paromomycin, and exhibited low cytotoxicity and good tolerability on intestinal murine organoids, which reveal the potential of these combinations for the treatment of leishmaniasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Leishmania | |
| 650 | 4 | |a drug combinations | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a intestinal organoids | |
| 650 | 4 | |a pyrvinium pamoate plus miltefosine | |
| 650 | 4 | |a pyrvinium pamoate plus paromomycin | |
| 700 | 1 | |a Galli, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Balaña-Fouce, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a García-Fernández, Nerea |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Valladares, María |e verfasserin |4 aut | |
| 700 | 1 | |a Reguera, Rosa M |e verfasserin |4 aut | |
| 700 | 1 | |a García-Estrada, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Pertejo, Yolanda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tropical medicine and infectious disease |d 2016 |g 9(2024), 2 vom: 25. Jan. |w (DE-627)NLM275181960 |x 2414-6366 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:2 |g day:25 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/tropicalmed9020030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 2 |b 25 |c 01 | ||